A more biovailable form of berberine
4.5 Impact of SGLT-2 inhibitors and GLP-1 receptor agonists on kidney function Multiple clinical trials have demonstrated the renoprotective effects of SGLT-2i and GLP-1 RAs in patients with T2DM and CKD
GLP-1s also reduce your appetite, so you end up eating less
The medication is currently being studied in the TRIUMPH Phase 3 clinical trial program, which is typically the final stage of testing before companies apply for FDA approval
[1] Commonly prescribed GLP-1 agonists include semaglutide (Ozempic for diabetes, Wegovy for weight management), dulaglutide (Trulicity), liraglutide (Victoza for diabetes, Saxenda for weight management), and exenatide (Byetta, Bydureon)
This finding is consistent with a floor effect for hepatic fat, which is unlikely to be reduced below the median of 2.1% observed in the large UK Biobank study 27